12:00 AM
Jan 07, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

FX006: Phase II data

Flexion reported data from a double-blind Phase II trial in 24 patients with OA of the knee showing that intra-articular injections of 10, 40 and 60 mg FX006 remained in the...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >